Angiotensin Converting Enzyme (ace) Affecting Patents (Class 514/16.3)
-
Patent number: 11389534Abstract: Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.Type: GrantFiled: August 27, 2018Date of Patent: July 19, 2022Assignee: Palo Alto InvestorsInventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Patent number: 10058562Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The method comprises administering an effective amount of a danazol compound to the animal accounting for the body fat content of the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal.Type: GrantFiled: April 27, 2016Date of Patent: August 28, 2018Assignee: Ampio Pharmaceuticals, Inc.Inventor: David Bar-Or
-
Patent number: 9511055Abstract: The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration.Type: GrantFiled: May 17, 2013Date of Patent: December 6, 2016Assignee: Tarix Pharmaceuticals Ltd.Inventor: Richard Franklin
-
Patent number: 8946162Abstract: The invention provides for innovative improvements in tumor therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.Type: GrantFiled: April 7, 2009Date of Patent: February 3, 2015Inventors: Evelyne Janzek-Hawlat, Hans Loibner, Manfred Schuster, Bernhard Peball
-
Patent number: 8940685Abstract: The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The components with molecular weight less than 1000 Da in the active peptides obtained according to the present method account for more than 92%, and alanine-tyrosine (Ala-Tyr, AY) as the characteristic peptide fragments in the antihypertensive peptides accounts for more than 0.6%, so that the active peptides have a good ACE inhibitory activity in vitro as well as stability against temperature, pH and major gastrointestinal digestive enzymes, and have a significant effect of lowering blood pressure on spontaneous hypertension rats in vivo. The active peptides can be applied as a new functional nutrient to development and production of food, health food and pharmaceutical.Type: GrantFiled: May 14, 2013Date of Patent: January 27, 2015Assignee: China National Research Institute of Food and Fermentation IndustriesInventors: Muyi Cai, Ruizeng Gu, Weixue Yi, Jun Lu, Yong Ma, Zhe Dong, Yaguang Xu, Xingchang Pan, Yongqing Ma, Feng Lin, Zhentao Jin, Liang Chen, Lu Lu, Wenying Liu
-
Patent number: 8889633Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.Type: GrantFiled: March 15, 2013Date of Patent: November 18, 2014Assignee: Mead Johnson Nutrition CompanyInventors: Dirk Hondmann, Eric A. F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method
Patent number: 8871818Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.Type: GrantFiled: October 21, 2008Date of Patent: October 28, 2014Assignees: Otsuka Pharmaceutical Co., Ltd.Inventors: Akira Tsuji, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku -
Publication number: 20140296151Abstract: The invention relates to a process of preparing low molecular weight peptides from gelatine. The gelatine is broken down into low molecular weight peptides using enzymes from Bacillus sp. to obtain peptides with low ash content. The gelatine is clarified by adjusting the pH to 7 using alkali hydroxide and filtered. The filtered solution is desalted at 20 to 55° C. in a diafiltration mode till the salt content decreases below 0.05% (w/v) The product so obtained is hydrolysed with an enzyme maintaining pH in the range of 7 to 10 and at temperature in the range of 25 to 75° C. The hydrolysed product is filtered through ultrafiltration membrane at temperature in the range of 15 to 55° C. and permeate is concentrateds at temperature in the range of 50 to 100° C. under vacuum to obtain the peptide solution of the invention.Type: ApplicationFiled: October 12, 2012Publication date: October 2, 2014Inventors: Ramchandra Vithal Gadre, Vithal Venkatrao Jogdand, Sanjay Narayan Nene
-
Patent number: 8835375Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.Type: GrantFiled: August 7, 2007Date of Patent: September 16, 2014Assignee: Applied Nanosystems B.V.Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
-
Publication number: 20140206618Abstract: The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.Type: ApplicationFiled: August 16, 2012Publication date: July 24, 2014Inventors: Alexander Pasternak, Timothy Blizzard, Harry Chobanian, Reynalda de Jesus, Fa-Xiang Ding, Shuzhi Dong, Candido Gude, Dooseop Kim, Haifeng Tang, Shawn Walsh, Barbara Pio, Jinlong Jiang
-
Patent number: 8759295Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: GrantFiled: May 21, 2010Date of Patent: June 24, 2014Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LPInventors: Soumitra S. Ghosh, Josue Alfaro-Lopez, Lawrence J. D'Souza, Odile Esther Levy, Qing Lin, Christopher J. Soares
-
Patent number: 8673862Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.Type: GrantFiled: September 6, 2012Date of Patent: March 18, 2014Assignee: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Hsiang-Ling Lai, Shiao-Cheng Chuang, Chien-Ti Chang, Ming-Yu Hung, Yu-Hui Liu, Su-Er Liou, Fu-Ning Chien, Chu-Chin Chen
-
Publication number: 20140066361Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.Type: ApplicationFiled: September 6, 2012Publication date: March 6, 2014Applicant: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTEInventors: YI-HONG CHEN, HSIANG-LING LAI, SHIAO-CHENG CHUANG, CHIEN-TI CHANG, MING-YU HUNG, YU-HUI LIU, SU-ER LIOU, FU-NING CHIEN, CHU-CHIN CHEN
-
Patent number: 8637463Abstract: The invention provides a peptide having an activity of inhibiting angiotensin-converting enzyme (ACE), and a food and drink and/or a pharmaceutical composition containing the peptide.Type: GrantFiled: December 1, 2004Date of Patent: January 28, 2014Assignee: Meiji Dairies CorporationInventors: Hidekazu Tonouchi, Masayuki Suzuki, Masayuki Uchida, Munehiro Oda
-
Publication number: 20140011742Abstract: A process for treating a protein before hydrolytic digestion, the process comprising exposing the protein to at least one cycle of microwave irradiation to produce a microwave treated protein containing one or more bioactive peptides. Further hydrolyzing the microwave treated protein to release at least one of the one or more bioactive peptides. A pharmaceutical composition, supplement and food product including the microwave treated protein or the one or more released bioactive peptides.Type: ApplicationFiled: December 8, 2011Publication date: January 9, 2014Applicant: MCGILL UNIVERSITYInventors: Jacqueline Sedman, Ashraf A. Ismail, Ahmed I. Gomaa
-
Patent number: 8580557Abstract: The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein hydrolysate of the present invention contains free amino acids and peptides, such as in vivo indigestible peptides including Xaa-Pro and Xaa-Pro-Pro, obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, and has ACE inhibitory activity or hypotensive effect.Type: GrantFiled: September 1, 2010Date of Patent: November 12, 2013Assignee: Calpis Co., Ltd.Inventors: Naoyuki Yamamoto, Seiichi Mizuno, Takanobu Gotou, Keiichi Matsuura, Tadashi Shinoda, Hideo Nishimura
-
Publication number: 20130281358Abstract: The invention provides a peptide comprising or consisting of SEQ ID NO: 1 and variants thereof, particularly comprising of consisting of the sequence FTY, nucleic acids encoding said peptides and pharmaceutical and nutraceutical compositions comprising said peptide(s) and/or nucleic acids. Also provided is the use of such a peptide in therapy and in vitro methods of ACE-inhibition.Type: ApplicationFiled: July 13, 2011Publication date: October 24, 2013Applicant: Marealis ASInventor: Jaran Rauo
-
Patent number: 8557958Abstract: The present invention relates to compositions and methods for treatment and/or prevention of diabetes or pre-diabetes. In particular, the invention provides compositions and methods for the treatment and/or prevention of diabetes or pre-diabetes, based on the use of angiotensin-(1-7) peptides, functional equivalents thereof, and/or angiotensin (1-7) agonists.Type: GrantFiled: February 1, 2013Date of Patent: October 15, 2013Assignee: Tarix Pharmaceuticals Ltd.Inventor: Richard Franklin
-
Patent number: 8425877Abstract: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT1-receptor antibody or an inhibitor of an AT1-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT1-receptor antibodies.Type: GrantFiled: July 31, 2007Date of Patent: April 23, 2013Assignee: CellTrend GmbHInventors: Kai Schulze-Forster, Harald Heidecke
-
Publication number: 20130012444Abstract: The present invention relates to crystalline solvates of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride, processes for their preparation and the use thereof.Type: ApplicationFiled: June 27, 2012Publication date: January 10, 2013Applicant: SANOFIInventors: Norbert NAGEL, Bruno BAUMGARTNER, Harald BERCHTOLD, Oliver PLETTENBURG, Dieter KADEREIT, Mandy MOHNICKE, Simon GESSLER, Joachim TILLNER
-
Publication number: 20120264694Abstract: A composition for the alleviation or treatment of one or more symptoms caused by one or more conditions or diseases selected from the group consisting of dilated cardiomyopathy, acquired or naturally occurring valvular disease, hypertrophic cardiomyopathy, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy and unclassified cardiomyopathy and combinations thereof. Also disclosed is a kit and a method for alleviating or treating the symptoms.Type: ApplicationFiled: April 12, 2012Publication date: October 18, 2012Applicant: EUROVET ANIMAL HEALTH B.V.Inventors: Marinus Maria Martinus BOEREN, Johanna Elisabeth Maria VERMEER, Henricus Franciscus Catharina MICHIELS
-
Publication number: 20120219514Abstract: In one aspect, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of a dermatological disorder, particularly by topical application of said ACE inhibitor and/or angiotensin II receptor antagonist. The present invention also provides cosmetic methods for improving and/or maintaining the skin tone of an individual suffering from, or at risk of suffering from, a dermatological disorder, said method comprising contacting the skin of said individual with an ACE inhibitor and/or angiotensin II receptor antagonist.Type: ApplicationFiled: November 18, 2011Publication date: August 30, 2012Inventor: Richard Bonnichsen
-
Publication number: 20120214734Abstract: The present invention provides methods for treating, preventing, and/or delaying the onset of metabolic disorders including multi-factorial syndromes such as insulin-insensitivity and metabolic syndrome by administering an effective amount of an ACE inhibitor.Type: ApplicationFiled: May 12, 2011Publication date: August 23, 2012Inventor: Paul Anthony TALBOT
-
Publication number: 20120195932Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated.Type: ApplicationFiled: January 25, 2010Publication date: August 2, 2012Applicant: BioDelivery Sciences International, Inc.Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
-
Publication number: 20120088730Abstract: The present invention relates to the discovery that the two ACE domains can have very different effects on cytokine expression. In one embodiment, the present invention provides a method of regulating and/or treating a condition in a subject by administering a therapeutically effective dosage of site specific ACE inhibitor. In another embodiment, the condition is inflammation and/or immune response.Type: ApplicationFiled: June 2, 2010Publication date: April 12, 2012Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Kenneth E. Bernstein, Chentao Lin